NASDAQ · AMRN
Amarin Corporation plc
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarThe next earnings date for AMRN has not been announced yet.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Dec 2026 | $-0.31 | $-0.31 | $-0.31 | 1 |
| Mar 2027 | $-0.18 | $-0.18 | $-0.18 | 1 |
| Jun 2027 | $-0.21 | $-0.21 | $-0.21 | 1 |
| Sep 2027 | $-0.21 | $-0.21 | $-0.21 | 1 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
Zacks · The Motley Fool · Fintel · MarketBeat- Zacks · Oct 29, 11:31 AM EDTAmarin's Q3 Earnings Beat Estimates, Revenues Miss MarkAMRN's Q3 2026 earnings surpass estimates despite declining revenues. Global Vascepa/Vazkepa demand grows 55% and cash reserves increase.
- The Motley Fool · Oct 28, 12:42 PM EDTAmarin (AMRN) Q3 2026 Earnings Call Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo
- Fintel · Oct 28, 11:52 AM EDTAmarin Corporation plc Reports Q3 2026 Financial ResultsAmarin Corporation plc reported its financial results for the third quarter ended September 30, 2026. Total Net Revenue for the quarter was $39.6 million, representing a decrease from $49.7 million in the third quarter of 2025. The company reported Net Loss of $0.2 million for th
- MarketBeat · Oct 28, 10:04 AM EDTWhat Amarin (AMRN) Said on Its Q3 Earnings Call3 Biotech Stocks Gaining MomentumAmarin (NASDAQ:AMRN) reported its first profitable quarter in two years for the third quarter of 2026, as lower operating expenses, positive operating cash flow and growth in international in-market demand helped offset continued U.S. pricing pres
- Zacks · Oct 15, 11:56 AM EDTFDA Expands ImmunityBio's Anktiva Label in Bladder CancerIBRX wins expanded FDA approval for Anktiva plus BCG, covering all patients with BCG-unresponsive NMIBC and broadening its commercial opportunity.
- Zacks · Oct 15, 10:04 AM EDTHere's Why You Should Add EYPT Stock to Your Portfolio NowEyePoint's Duravyu faces a key LUCIA study data readout in late 2026, with results potentially paving the way for an NDA filing in 2027.
- Zacks · Oct 15, 9:33 AM EDTRARE's Fayuvi Approval Spurs Second PRV Sale Worth $203M in a WeekUltragenyx agrees to sell its Fayuvi-linked PRV for $203 million, marking its second voucher sale in one week and adding non-dilutive funding for rare-disease programs.
- Zacks · Oct 14, 12:38 PM EDTLQDA Settles UTHR Disputes for $380.7M, Limits Yutrepia LabelLiquidia settles six legal disputes with United Therapeutics, securing Yutrepia access for PAH patients but facing $380.7 million in payments and a narrower drug label.
- Zacks · Oct 14, 8:59 AM EDTHere's Why You Should Add ANRO Stock to Your Portfolio NowAlto advances its depression drug pipeline, with key 2027 study results ahead for ALTO-207, ALTO-300 and ALTO-100.
- Zacks · Oct 14, 8:52 AM EDTSyndax Stock Falls 16% as Phase II Fibrosis Study Misses Primary GoalSNDX shares plunge 16% as its phase II axatilimab study misses the primary endpoint, prompting the company to abandon development in idiopathic pulmonary fibrosis.
- Zacks · Oct 13, 12:40 PM EDTBMY Reports Mixed Phase III Trial Results, Stock DownBristol Myers Squibb reports mixed Phase III results for admilparant in IPF, while RYZ101 delivers a significant win in advanced GEP-NETs.
- Zacks · Oct 12, 11:24 AM EDTPrime Medicine Stock Rallies Nearly 26% in a Month: Here's WhyPRME shares jump nearly 26% in a month as FDA clearance for PM647 and PM577a's clinical debut advances its gene-editing pipeline.
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Amarin Corporation plc from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.